Bispecifics reshape relapsed lymphoma care
T-cell engaging bispecifics are settling into routine third-line and later care for diffuse large B-cell and follicular lymphoma.
Relapsed lymphoma care now has bispecifics as a routine option in third line and later, often before or alongside cell therapy. The clinical question - which patient goes to bispecific vs CAR-T, in which order - is what community haematology is now operationalising.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- SnapshotAdult diffuse glioma therapy reference (2026)
- ExplainedWhat is glioblastoma?
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.